Quantbot Technologies LP Sells 34,661 Shares of Certara, Inc. (NASDAQ:CERT)

Quantbot Technologies LP cut its stake in shares of Certara, Inc. (NASDAQ:CERT - Free Report) by 37.3% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund owned 58,227 shares of the company's stock after selling 34,661 shares during the period. Quantbot Technologies LP's holdings in Certara were worth $620,000 as of its most recent filing with the SEC.

A number of other hedge funds have also recently bought and sold shares of CERT. Charles Schwab Investment Management Inc. grew its position in shares of Certara by 1.9% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 699,575 shares of the company's stock valued at $8,192,000 after acquiring an additional 12,720 shares during the period. Glenmede Trust Co. NA raised its stake in Certara by 78.6% in the 3rd quarter. Glenmede Trust Co. NA now owns 1,206,069 shares of the company's stock valued at $14,123,000 after acquiring an additional 530,598 shares during the period. Edgestream Partners L.P. acquired a new stake in Certara during the 3rd quarter valued at $1,782,000. Wasatch Advisors LP boosted its position in Certara by 22.4% during the third quarter. Wasatch Advisors LP now owns 9,015,941 shares of the company's stock worth $105,577,000 after purchasing an additional 1,651,076 shares during the period. Finally, 272 Capital LP bought a new position in Certara during the third quarter worth $177,000. 73.96% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

CERT has been the topic of several research analyst reports. Barclays increased their price objective on shares of Certara from $12.00 to $13.00 and gave the company an "equal weight" rating in a research report on Friday, February 28th. Stephens restated an "overweight" rating and set a $17.00 price objective on shares of Certara in a research report on Thursday, February 27th. TD Cowen assumed coverage on Certara in a report on Thursday, February 27th. They set a "buy" rating and a $16.00 price objective for the company. Finally, William Blair reiterated a "market perform" rating on shares of Certara in a research note on Thursday, February 27th. Four research analysts have rated the stock with a hold rating and four have issued a buy rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $15.83.

Remove Ads

Certara Price Performance

Shares of Certara stock traded down $0.01 during midday trading on Monday, hitting $9.90. 1,579,830 shares of the company traded hands, compared to its average volume of 1,038,416. The stock has a market cap of $1.59 billion, a price-to-earnings ratio of -49.50, a PEG ratio of 9.29 and a beta of 1.60. The company has a debt-to-equity ratio of 0.28, a quick ratio of 2.86 and a current ratio of 2.86. The firm's fifty day moving average price is $12.40 and its 200-day moving average price is $11.44. Certara, Inc. has a 12 month low of $9.41 and a 12 month high of $19.18.

Certara Company Profile

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.